Abstract
Oral estrogens were the treatment of choice for carcinoma of the prostate for over four decades, but were abandoned because of an excess of cardiovascular and thromboembolic toxicity. It is now recognized that most of this toxicity is related to the first pass portal circulation, which upregulates the hepatic metabolism of hormones, lipids and coagulation proteins. Most of this toxicity can be avoided by parenteral (intramuscular or transdermal) estrogen administration, which avoids hepatic enzyme induction. It also seems that a short-term but modest increase in cardiovascular morbidity (but not mortality) is compensated for by a long-term cardioprotective benefit, which accrues progressively as vascular remodeling develops over time. Parenteral estrogen therapy has the advantage of giving protection against the effects of andropause (similar to the female menopause), which are induced by conventional androgen suppression and include osteoporotic fracture, hot flashes, asthenia and cognitive dysfunction. In addition, parenteral estrogen therapy is significantly cheaper than contemporary endocrine therapy, with substantive economic implications for health providers.
Key Points
-
Oral estrogens were abandoned as first-line hormone therapy for CaP because of their cardiovascular and thromboembolic toxicity
-
Thromboembolic toxicity during first pass absorption of estrogens from the gut necessitates the need for parenteral routes of administration, which reduce thromboembolic risk
-
Cardiovascular toxicity is related to estrogen-mediated vascular effects, which are both dose-dependent and time-dependent. Whilst short-term estrogen therapy has an increased risk of cardiovascular toxicity, long-term estrogen therapy may be associated with a cardiovascular benefit
-
Current conventional androgen deprivation therapy is associated with considerable morbidity (castration syndrome/andropause) resulting in osteoporosis, hot flashes, cognitive dysfunction, asthenia and anemia
-
Estrogen therapy is protective against the andropausal side effects of current hormone therapies
-
Estrogen therapy is cheap with substantial health-care economic implications
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Huggins C and Hodges CV (1941) Studies on prostatic cancer I: effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293–297
Nesbit RM and Plumb RT (1946) Prostatic carcinoma, follow-up on 795 patients treated prior to the endocrine era and comparison of survival rates between these and patients treated by endocrine therapy. Surgery 20: 263–272
Nesbit RM and Baum WC (1950) Endocrine control of prostatic carcinoma, clinical and statistical survey of 1518 cases. JAMA 143: 1317–1320
The Veterans Administration Co-operative Urological Research Group 1967 (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124: 1011–1017
Bailar JC III and Byar DP (1970) Estrogen treatment for cancer of the prostate: early results with 3 doses of diethylstilbestrol and placebo. Cancer 26: 257–261
Byar DP (1973) Proceedings: the Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 32: 1126–1130
Diamond T et al. (1998) The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 83: 1561–1566
Daniell HW et al. (2000) Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163: 181–186
Fossa SD et al. (1994) Assessment of quality of life in patients with prostate cancer. Semin Oncol 21: 657–661
Melmed GY et al. (2002) Quality of life at the end of life: trends in patients with metastatic prostate cancer. Urology 59: 103–109
Bolla M et al. (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337: 295–300
The Medical Research Council Prostate Cancer Working Party Investigators Group (1997) Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 79: 235–246
Messing EM et al. (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341: 1781–1788
Mijatovic V and Pines A (1999) The first clinical synthesis conference on hormone replacement therapy: new perspectives for HRT? Maturitas 33: 87–92
Shearer RJ et al. (1973) Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer. Br J Urol 45: 668–677
Smith PH et al. (1984) Estramustine phosphate in prostate cancer. EORTC experience: preliminary results of Protocol 30762. Urology 23: 64–68
de Voogt HJ et al. (1986) Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 135: 303–307
Peeling WB (1989) Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology 33: 45–52
Pavone-Macaluso M et al. (1989) EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group. Prog Clin Biol Res 303: 111–116
Robinson MR et al. (1995) The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol 28: 273–283
Bishop MC et al. (1989) Oestrogen dosage in prostatic cancer: the threshold effect? Br J Urol 64: 290–296
Cox RL and Crawford ED (1995) Estrogens in the treatment of prostate cancer. J Urol 154: 1991–1998
Henriksson P et al. (1988) Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate. Prostate 13: 257–261
Stege R et al. (1988) Single drug polyestradiol phosphate therapy in prostatic cancer. Am J Clin Oncol 11 (Suppl 2): S101–S103
Stege R et al. (1989) Single-drug parenteral estrogen treatment in prostatic cancer: a study of two maintenance-dose regimens. Prostate 14: 183–188
Ockrim JL et al. (2003) Transdermal estradiol therapy for advanced prostate cancer—forward to the past? J Urol 169: 1735–1737
Carlstrom K et al. (1989) A comparison of androgen status in patients with prostatic cancer treated with oral and/or parenteral estrogens or by orchidectomy. Prostate 14: 177–182
von Schoultz B et al. (1989) Estrogen therapy and liver function—metabolic effects of oral and parenteral administration. Prostate 14: 389–395
Henriksson P et al. (1990) Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma. Br J Urol 65: 282–285
Aro J et al. (1990) Effects of orchiectomy and polyestradiol phosphate therapy on serum lipoprotein lipids and glucose tolerance in prostatic cancer patients. Eur Urol 17: 229–235
Ockrim JL et al. (2005) Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism. J Urol 174: 527–533
van Kesteren PJ et al. (1997) Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 47: 337–342
Volterrani M et al. (1995) Estrogen acutely increases peripheral blood flow in postmenopausal women. Am J Med 99: 119–122
Collins P (1996) Vascular aspects of oestrogen. Maturitas 23: 217–226
Hedlund PO and Henriksson P (2000) Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study. Urology 55: 328–333
Mikkola AK et al. (1998) Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group. Br J Urol 82: 63–68
Bracamonte MP and Miller VM (2001) Vascular effects of estrogens: arterial protection versus venous thrombotic risk. Trends Endocrinol Metab 12: 204–209
Ockrim JL et al. (2006) Changes in vascular flow after transdermal oestradiol therapy for prostate cancer: a mechanism for cardiovascular toxicity and benefit? BJU Int 97: 498–504
Barrett-Connor E and Grady D (1998) Hormone replacement therapy, heart disease, and other considerations. Ann Rev Public Health 19: 55–72
Hulley S et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280: 605–613
Grodstein F et al. (2001) Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study: a prospective, observational study. Ann Intern Med 135: 1–8
Emmans-Dean M et al. (2006) Parental oestrogens for prostate cancer: a systematic review of clinical effectiveness and dose response. Centre for Reviews and Dissemination. CRD Report 33; York: University of York
Mikkola A et al. (2005) Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate. Scand J Urol Nephrol 39: 294–300
Aro J (1991) Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population. Prostate 18: 131–137
Henriksson P et al. (1999) Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics, and endocrine and clinical effects, of a parenteral estrogen regimen. Prostate 40: 76–82
Hedlund PO et al. (2002) Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer. Scandinavian Prostatic Cancer Group (SPCG) Study No 5. Scand J Urol Nephrol 36: 405–413
Wasson JH et al. (1998) Androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era: a national survey of urologist beliefs and practices. J Urol 159: 1993–1996
Goldray D et al. (1993) Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH). J Clin Endocrinol Metab 76: 288–290
Smith MR et al. (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345: 948–955
Center JR et al. (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353: 878–882
Melton LJ III et al. (2003) Fracture risk following bilateral orchiectomy. J Urol 169: 1747–1750
Ockrim JL et al. (2004) Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer. J Urol 172: 2203–2207
Karling P et al. (1994) Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol 152: 1170–1173
Spetz AC et al. (2001) Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol 166: 517–520
Gerber GS et al. (2000) Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology 55: 97–101
McLeod DG and Iversen P (2000) Gynecomastia in patients with prostate cancer: a review of treatment options. Urology 56: 713–720
Boccon-Gibod L (1998) Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer? Eur Urol 33: 159–164
Perdona S et al. (2005) Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol 6: 295–300
Litwin MS et al. (1998) Quality-of-life outcomes in long-term survivors of advanced prostate cancer. Am J Clin Oncol 21: 327–332
Fossa SD et al. (2000) Quality of life of patients with newly diagnosed poor prognosis M1 prostate cancer undergoing orchiectomy without or with mitomycin C: results from the EORTC Phase-III trial 30893. Eur Urol 37: 541–551
Cassileth BR et al. (1992) Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual Life Res 1: 323–329
Herr HW et al. (1993) A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer 71: 1143–1150
Moinpour CM et al. (1998) Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst 90: 1537–1544
Boccardo F et al. (1999) Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 17: 2027–2038
Ockrim JO (2004) Transdermal oestradiol therapy for the treatment of advanced prostate cancer [thesis]. London: University of London
Bayoumi AM et al. (2000) Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 92: 1731–1739
Walsh PC et al. (2001) A structured debate: immediate versus deferred androgen suppression in prostate cancer: evidence for deferred treatment. J Urol 166: 508–515
Trump DL (2005) Editorial comment. J Urol 174: 532–533
Haapiainen R et al. (1990) Comparison of primary orchiectomy and polyoestradiol phosphate in the treatment of advanced prostatic cancer. Finnprostate Group. Br J Urol 66: 94–97
Aro J et al. (1993) Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group. Ann Chir Gynaecol Suppl 206: 5–8
Lukkarinen O and Kontturi M (1994) Comparison of a long-acting LHRH agonist and polyoestradiol phosphate in the treatment of advanced prostatic carcinoma: an open prospective, randomized multicentre study. Scand J Urol Nephrol 28: 171–178
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P Abel is the principal investigator on a Cancer Research UK grant for a phase II randomized control trial of estrogen patches versus luteinizing hormone-releasing hormone. The other authors declared they have no competing interests.
Rights and permissions
About this article
Cite this article
Ockrim, J., Lalani, EN. & Abel, P. Therapy Insight: parenteral estrogen treatment for prostate cancer—a new dawn for an old therapy. Nat Rev Clin Oncol 3, 552–563 (2006). https://doi.org/10.1038/ncponc0602
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0602
This article is cited by
-
Estrogens and prostate cancer
Prostate Cancer and Prostatic Diseases (2019)
-
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
Advances in Therapy (2016)
-
Parenteral oestrogen in the treatment of prostate cancer: a systematic review
British Journal of Cancer (2008)
-
AP-2 regulates the transcription of estrogen receptor (ER)-β by acting through a methylation hotspot of the 0N promoter in prostate cancer cells
Oncogene (2007)